Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Targeted therapy is a treatment that targets the cancer?s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and tries to limit damage to healthy cells.
This report contains market size and forecasts of Targeted Therapy for Bladder Cancer in Global, including the following market information:
Global Targeted Therapy for Bladder Cancer Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Targeted Therapy for Bladder Cancer market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Atezolizumab (Tecentriq) Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Targeted Therapy for Bladder Cancer include Pfizer, Merck KGaA, Roche, Astellas, Janssen Biotech, Bristol-Myers Squibb, Merck & Co. and Gilead Sciences, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Targeted Therapy for Bladder Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Targeted Therapy for Bladder Cancer Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Targeted Therapy for Bladder Cancer Market Segment Percentages, by Type, 2022 (%)
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Erdafitinib (Balversa)
Other
Global Targeted Therapy for Bladder Cancer Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Targeted Therapy for Bladder Cancer Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Other
Global Targeted Therapy for Bladder Cancer Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Targeted Therapy for Bladder Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Targeted Therapy for Bladder Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Targeted Therapy for Bladder Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Merck KGaA
Roche
Astellas
Janssen Biotech
Bristol-Myers Squibb
Merck & Co.
Gilead Sciences
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Targeted Therapy for Bladder Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Targeted Therapy for Bladder Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Targeted Therapy for Bladder Cancer Overall Market Size
2.1 Global Targeted Therapy for Bladder Cancer Market Size: 2022 VS 2030
2.2 Global Targeted Therapy for Bladder Cancer Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Targeted Therapy for Bladder Cancer Players in Global Market
3.2 Top Global Targeted Therapy for Bladder Cancer Companies Ranked by Revenue
3.3 Global Targeted Therapy for Bladder Cancer Revenue by Companies
3.4 Top 3 and Top 5 Targeted Therapy for Bladder Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Targeted Therapy for Bladder Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Targeted Therapy for Bladder Cancer Players in Global Market
3.6.1 List of Global Tier 1 Targeted Therapy for Bladder Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Targeted Therapy for Bladder Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Targeted Therapy for Bladder Cancer Market Size Markets, 2022 & 2030
4.1.2 Atezolizumab (Tecentriq)
4.1.3 Avelumab (Bavencio)
4.1.4 Erdafitinib (Balversa)
4.1.5 Other
4.2 By Type - Global Targeted Therapy for Bladder Cancer Revenue & Forecasts
4.2.1 By Type - Global Targeted Therapy for Bladder Cancer Revenue, 2018-2023
4.2.2 By Type - Global Targeted Therapy for Bladder Cancer Revenue, 2023-2030
4.2.3 By Type - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Targeted Therapy for Bladder Cancer Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application - Global Targeted Therapy for Bladder Cancer Revenue & Forecasts
5.2.1 By Application - Global Targeted Therapy for Bladder Cancer Revenue, 2018-2023
5.2.2 By Application - Global Targeted Therapy for Bladder Cancer Revenue, 2023-2030
5.2.3 By Application - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Targeted Therapy for Bladder Cancer Market Size, 2022 & 2030
6.2 By Region - Global Targeted Therapy for Bladder Cancer Revenue & Forecasts
6.2.1 By Region - Global Targeted Therapy for Bladder Cancer Revenue, 2018-2023
6.2.2 By Region - Global Targeted Therapy for Bladder Cancer Revenue, 2023-2030
6.2.3 By Region - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Targeted Therapy for Bladder Cancer Revenue, 2018-2030
6.3.2 US Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.3.3 Canada Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.3.4 Mexico Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Targeted Therapy for Bladder Cancer Revenue, 2018-2030
6.4.2 Germany Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.4.3 France Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.4.4 U.K. Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.4.5 Italy Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.4.6 Russia Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.4.7 Nordic Countries Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.4.8 Benelux Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Targeted Therapy for Bladder Cancer Revenue, 2018-2030
6.5.2 China Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.5.3 Japan Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.5.4 South Korea Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.5.5 Southeast Asia Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.5.6 India Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Targeted Therapy for Bladder Cancer Revenue, 2018-2030
6.6.2 Brazil Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.6.3 Argentina Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Targeted Therapy for Bladder Cancer Revenue, 2018-2030
6.7.2 Turkey Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.7.3 Israel Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.7.4 Saudi Arabia Targeted Therapy for Bladder Cancer Market Size, 2018-2030
6.7.5 UAE Targeted Therapy for Bladder Cancer Market Size, 2018-2030
7 Players Profiles
7.1 Pfizer
7.1.1 Pfizer Corporate Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Targeted Therapy for Bladder Cancer Major Product Offerings
7.1.4 Pfizer Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News
7.2 Merck KGaA
7.2.1 Merck KGaA Corporate Summary
7.2.2 Merck KGaA Business Overview
7.2.3 Merck KGaA Targeted Therapy for Bladder Cancer Major Product Offerings
7.2.4 Merck KGaA Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.2.5 Merck KGaA Key News
7.3 Roche
7.3.1 Roche Corporate Summary
7.3.2 Roche Business Overview
7.3.3 Roche Targeted Therapy for Bladder Cancer Major Product Offerings
7.3.4 Roche Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.3.5 Roche Key News
7.4 Astellas
7.4.1 Astellas Corporate Summary
7.4.2 Astellas Business Overview
7.4.3 Astellas Targeted Therapy for Bladder Cancer Major Product Offerings
7.4.4 Astellas Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.4.5 Astellas Key News
7.5 Janssen Biotech
7.5.1 Janssen Biotech Corporate Summary
7.5.2 Janssen Biotech Business Overview
7.5.3 Janssen Biotech Targeted Therapy for Bladder Cancer Major Product Offerings
7.5.4 Janssen Biotech Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.5.5 Janssen Biotech Key News
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Corporate Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Major Product Offerings
7.6.4 Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.6.5 Bristol-Myers Squibb Key News
7.7 Merck & Co.
7.7.1 Merck & Co. Corporate Summary
7.7.2 Merck & Co. Business Overview
7.7.3 Merck & Co. Targeted Therapy for Bladder Cancer Major Product Offerings
7.7.4 Merck & Co. Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.7.5 Merck & Co. Key News
7.8 Gilead Sciences
7.8.1 Gilead Sciences Corporate Summary
7.8.2 Gilead Sciences Business Overview
7.8.3 Gilead Sciences Targeted Therapy for Bladder Cancer Major Product Offerings
7.8.4 Gilead Sciences Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.8.5 Gilead Sciences Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Targeted Therapy for Bladder Cancer Market Opportunities & Trends in Global Market
Table 2. Targeted Therapy for Bladder Cancer Market Drivers in Global Market
Table 3. Targeted Therapy for Bladder Cancer Market Restraints in Global Market
Table 4. Key Players of Targeted Therapy for Bladder Cancer in Global Market
Table 5. Top Targeted Therapy for Bladder Cancer Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Targeted Therapy for Bladder Cancer Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Targeted Therapy for Bladder Cancer Revenue Share by Companies, 2018-2023
Table 8. Global Companies Targeted Therapy for Bladder Cancer Product Type
Table 9. List of Global Tier 1 Targeted Therapy for Bladder Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Targeted Therapy for Bladder Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2023-2030
Table 14. By Application ? Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2023-2030
Table 17. By Region ? Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Targeted Therapy for Bladder Cancer Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Targeted Therapy for Bladder Cancer Revenue (US$, Mn), 2023-2030
Table 20. By Country - North America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2023-2030
Table 22. By Country - Europe Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2023-2030
Table 24. By Region - Asia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2023-2030
Table 26. By Country - South America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2023-2030
Table 28. By Country - Middle East & Africa Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2023-2030
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Targeted Therapy for Bladder Cancer Product Offerings
Table 32. Pfizer Targeted Therapy for Bladder Cancer Revenue (US$, Mn), (2018-2023)
Table 33. Merck KGaA Corporate Summary
Table 34. Merck KGaA Targeted Therapy for Bladder Cancer Product Offerings
Table 35. Merck KGaA Targeted Therapy for Bladder Cancer Revenue (US$, Mn), (2018-2023)
Table 36. Roche Corporate Summary
Table 37. Roche Targeted Therapy for Bladder Cancer Product Offerings
Table 38. Roche Targeted Therapy for Bladder Cancer Revenue (US$, Mn), (2018-2023)
Table 39. Astellas Corporate Summary
Table 40. Astellas Targeted Therapy for Bladder Cancer Product Offerings
Table 41. Astellas Targeted Therapy for Bladder Cancer Revenue (US$, Mn), (2018-2023)
Table 42. Janssen Biotech Corporate Summary
Table 43. Janssen Biotech Targeted Therapy for Bladder Cancer Product Offerings
Table 44. Janssen Biotech Targeted Therapy for Bladder Cancer Revenue (US$, Mn), (2018-2023)
Table 45. Bristol-Myers Squibb Corporate Summary
Table 46. Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Product Offerings
Table 47. Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Revenue (US$, Mn), (2018-2023)
Table 48. Merck & Co. Corporate Summary
Table 49. Merck & Co. Targeted Therapy for Bladder Cancer Product Offerings
Table 50. Merck & Co. Targeted Therapy for Bladder Cancer Revenue (US$, Mn), (2018-2023)
Table 51. Gilead Sciences Corporate Summary
Table 52. Gilead Sciences Targeted Therapy for Bladder Cancer Product Offerings
Table 53. Gilead Sciences Targeted Therapy for Bladder Cancer Revenue (US$, Mn), (2018-2023)
List of Figures
Figure 1. Targeted Therapy for Bladder Cancer Segment by Type in 2022
Figure 2. Targeted Therapy for Bladder Cancer Segment by Application in 2022
Figure 3. Global Targeted Therapy for Bladder Cancer Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Targeted Therapy for Bladder Cancer Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Targeted Therapy for Bladder Cancer Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Targeted Therapy for Bladder Cancer Revenue in 2022
Figure 8. By Type - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
Figure 9. By Application - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
Figure 10. By Region - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
Figure 11. By Country - North America Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
Figure 12. US Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 13. Canada Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 14. Mexico Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 15. By Country - Europe Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
Figure 16. Germany Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 17. France Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 18. U.K. Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 19. Italy Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 20. Russia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 21. Nordic Countries Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 22. Benelux Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 23. By Region - Asia Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
Figure 24. China Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 25. Japan Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 26. South Korea Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 27. Southeast Asia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 28. India Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 29. By Country - South America Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
Figure 30. Brazil Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 31. Argentina Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 32. By Country - Middle East & Africa Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2030
Figure 33. Turkey Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 34. Israel Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 35. Saudi Arabia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 36. UAE Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2030
Figure 37. Pfizer Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 38. Merck KGaA Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 39. Roche Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 40. Astellas Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 41. Janssen Biotech Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Merck & Co. Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Gilead Sciences Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
